Medtronic has started enrolment in a clinical trial intended to evaluate its ECG Belt Research System as a diagnostic to optimise cardiac resynchronisation therapy (CRT) for heart failure.

Referred to as ECG Belt for CRT Response, the prospective, randomised, interventional trial is designed to initially compare CRT and ECG Belt diagnostics treatment with standard CRT in ten subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medtronic plans to expand the trial to additional sites globally to recruit a total of 400 patients. The first participant has been enrolled at the Mercy Medical Center in the US.

“The diagnostic tool will be applied during the implantation of a CRT device. The Belt will be externally wrapped around the patient’s chest and back to guide the left ventricular lead placement.”

First site principal investigator Troy Hounshell said: “The aim of this technology is to give physicians immediate feedback that may impact clinical decision making at the time of implant and also during follow-up visits.

“By pairing CRT with the ECG Belt, we have the potential to provide a more personalised and non-invasive approach to help heart failure patients.”

During the trial, the ECG Belt will be used for synchronisation measurements in real-time in order to evaluate the electrical activity of the heart.

The diagnostic tool will be applied during the implantation of a CRT device. The Belt will be externally wrapped around the patient’s chest and back to guide the left ventricular lead placement.

ECG Belt will be additionally used at follow-up visits to perform further optimisation of the device’s programmed settings.

Medtronic Cardiac Resynchronization Therapy business vice-president and general manager Kweli Thompson said: “Our goal for this study is to give clinicians real-time insights to address each patient’s needs and to help optimise CRT for heart failure patients.”